공시 • Nov 06
BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025 BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israel 공시 • Oct 08
Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million. DR.Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million on October 6, 2025. Under the terms of the Sale Agreement, the Group will sell AMS to Dr. Zvi Marom, a non-executive director and significant shareholder of the Group, in exchange for his entire shareholding of 96,794,500 ordinary shares of in BATM, representing c. 22.2% of the existing issued share capital. The transaction values AMS at £17.6m, based on the closing price of the Group's Ordinary Shares. Following completion, Dr. Marom will cease to be a shareholder of the Group and will resign as a director of the Group. The completion of the sale is subject to the approval of shareholders at a general meeting and and all other legal and regulatory requirements; the Board will issue a circular to convene this general meeting in due course.
Mark Percy, Anita Ghanekar, James Thomas acted as advisor to BATM Advanced Communications. 공시 • Sep 27
BATM Advanced Communications Ltd. Announces Board and Committee Changes BATM Advanced Communications Ltd. announced that Harel Locker is retiring from his position as an external director, as defined under Israeli law, of the Group with immediate effect. Mr. Locker completes his third three-year term as an external director of BATM. External directors under Israeli law are appointed for a minimum of one three-year term, which may be extended by the company (subject to shareholder approval) for no more than two additional terms of three years each. The Board will propose the appointment of a new external director for approval by shareholders at the Group's next annual general meeting. Following Mr. Locker's retirement from the Board, Prof. Varda Shalev, an external director of BATM, will assume the role of Interim Chair of the Audit Committee and a permanent chair will be appointed in due course. 공시 • Jul 24
BATM Advanced Communications Ltd. to Report First Half, 2025 Results on Aug 18, 2025 BATM Advanced Communications Ltd. announced that they will report first half, 2025 results on Aug 18, 2025 공시 • Mar 05
BATM Advanced Communications Ltd. to Report Fiscal Year 2024 Results on Mar 17, 2025 BATM Advanced Communications Ltd. announced that they will report fiscal year 2024 results on Mar 17, 2025 공시 • Dec 19
BATM Approves the Appointment of Shmuel Ben Zvi as Non-Executive Director of the Group BATM at its Annual General Meeting held on 19 December 2024, approved the appointment of Dr. Shmuel (Muli) Ben Zvi as a Non-executive Director of the Group with effect from the conclusion of the Meeting. 공시 • Dec 12
BATM Advanced Communications Limited Announces Commencement of Natslab Molecular Biology Platform BATM Advanced Communications Limited announced that the NATlab molecular biology platform being developed by ADOR Diagnostics ("ADOR"), an associate company of the Group, has commenced pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy. This marks a key milestone in the development of NATlab and, the Group believes, will enable initial sales as well as increase industry awareness and interest from prospective partners. The advanced NATlab molecular biology platform is a point-of-care sample-to-answer solution designed to provide rapid and accurate diagnosis of infectious disease. It uses a patented isothermal amplification method for syndromic multiplex diagnostics to be able to rapidly identify a broad range of pathogens from a single test. The commencement of the pre-clinical validation phase follows the successful completion of pre-clinical trials, which were conducted at the Tzafom Medical Center in Israel, to confirm the validity of the biological process that ADOR has developed and that it can be performed within the NATlab cartridge and analyser device. NATlab identified all negative samples and had a 97% sensitivity for the positive samples, confirming the efficacy of the system and its ability to out-perform competing solutions available in the market because of its multiplex diagnostic capability for rapid and accurate diagnosis. ADOR has now made significant progress with NATlab with the full system entering the pre-clinical validation phase at the Lazzaro Sp allanzani National Institute forinfectious Diseases in Rome, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market. In addition, following the success of the pre-clinical trials, ADOR, in collaboration with the Tzafom Medical center, has received a grant from the Israel Innovation Authority to develop a NATlab panel for the diagnosis of stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is to be granted over two years based on the achievement of milestones. 공시 • Nov 15
BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024 BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israel 공시 • Aug 19
BATM Advanced Communications Ltd. Provides Earnings Guidance for the Second Half of 2024 BATM Advanced Communications Ltd. provided earnings guidance for the second half of 2024. For the period, the company expects increase in revenue. 공시 • May 03
BATM Advanced Communications Ltd. Selected for Tb Diagnostics Programme BATM announce that the Group has been selected for aprestigious programme, that is receiving funding from the European Union, for the development of an advanced tuberculosis ("TB") diagnostics solution. The Group has also been awarded a grant of €0.5 million towards the initial 18 months of the programme with the potential for additional funding to be awarded thereafter for the next stage. The Group was selected by the National Research Council of Italy (Consiglio Nazionale delle Ricerche) ("CNR") under a competitive process involving many companies and after a lengthy and detailed verification phase to participate in the programme alongside one of CNR's research institutes, the Institute for System Analysis and Computer Science (Istituto di Analisi dei Sistemi ed Informatica) ("IASI"). The Group's participation reflects its strategy to advance the BATM diagnostics division through developing advanced molecular diagnostics solutions for substantial infectious disease markets, with the global diagnostics market for TB being worth over $2 billion. It is also demonstrative of the steps that the Group is taking to drive long-term sustainable growth through investing in constant innovation to maintain the diagnostics division's technological edge. The programme is for the development of a diagnostics system, based on the Rolling Circle Amplification ("RCA") method, for the rapid identification of TB and multi-drug resistant TB. This builds on the existing work of the BATM diagnostics division for the development of a rapid, RCA-based sample-to-answer diagnostic solution for TB and multi-drug resistant TB. The programme is receiving funding from the European Regional Development Fund via the Lazio Regional Operational Program of the Lazio regional government. 공시 • Feb 29
BATM Advanced Communications Ltd. to Report Fiscal Year 2023 Results on Mar 12, 2024 BATM Advanced Communications Ltd. announced that they will report fiscal year 2023 results on Mar 12, 2024